| ||||||
| 11494 Sorrento Valley Rd, San Diego, CA, 92121-1318, US. TEL: 858-597-6006 http://www.genetronics.com | ||||||
| Last Sale | Net Change | % Change | Volume | Last Updated | ||
|---|---|---|---|---|---|---|
| N.A. | N.A. | N.A. | N.A. | N.A. | ||
| ||||||||||||||||||||||
 |
|
||||||||||||||||||||||
| ||||
| Security Type | Common Stock | Specialist | 985 | |
| Industry | Health Services, Pharmaceuticals, and Medical Diagnostics | Trading Post | 15 | |
| Primary Exchange | Amex | SEC Filings | ||
| ||||
| Description |
|
Genetronics Biomedical Corp. is a biomedical company whose technology platform is based on medical devices that use Electroporation Therapy (EPT) to deliver drugs and genes into cells. The company is developing and commercializing novel medical therapies to address a number of critical unmet treatment needs using EPT. The company's MedPulser System is in late stage development in the U.S. for the treatment of head and neck cancer. This system delivers electrical pulses to tumors injected with the generic drug bleomycin. The unique feature of the system, which uses a generator together with disposable needle applicators, is the preservation of healthy tissue at the margins of the tumor. The company believes this may afford distinct advantages over surgery in preserving function and improving the quality of life for cancer patients who would otherwise face significant morbidity associated with cancer surgery. The company believes that the planned commercial launch of its CE certified MedPulser System in Europe in 2005 represents an important milestone. The company has also been developing devices for the delivery of DNA for DNA vaccinations and gene therapy. Genetronics believe that attempts to pioneer new therapies based on DNA have been hampered by the use of viral vectors to deliver DNA. In addition to safety issues, viral vectors are difficult and expensive to manufacture. Because electroporation has proven efficient and safe in animal experiments, the company is developing a MedPulser DNA Delivery System. By engineering different applicators, the company can deliver DNA to the muscle, skin or vasculature. This should facilitate attempts to use DNA for therapies ranging from vaccination to gene therapy of single or multiple gene defects, including cancer and vascular diseases. During the first quarter of 2004, the company initiated two Phase III head and neck clinical trials in the U.S. and Europe. On Feb. 23, 2004, Genetronics announced that it had completed the Special Protocol Assessment review process with the FDA for the two Phase III pivotal studies to evaluate the use of the company's MedPulser Electroporation Therapy System as a treatment for recurrent and second primary squamous cell carcinomas of the head and neck (SCCHN). On Mar. 1, 2004, the company announced that we have begun treating patients with primary or recurrent SCCHN in a post European regulatory approval clinical study. The clinical study is designed to support the commercialization of the MedPulser Electroporation System in the European Union. |
| Quote |
| ||||
| Last Sale | N.A. (N.A.) | |||
| Net Change | N.A. | |||
| % Change | N.A. | |||
| Previous Close | N.A. | |||
| Today’s Open | N.A. | |||
| Today’s High | N.A. | |||
| Today’s Low | N.A. | |||
| Volume | N.A. | |||
| 52 Week High | N.A. | |||
| 52 Week Low | N.A. | |||
| ||||
| Chart |
| 3mo | 6mo | 12mo | 24mo | 36mo | 48mo | 60mo |
|
| Click here to view the data behind the chart. |
| Fundamentals |
|
||||
| P/E ratio | N.A. | Short Interest | N.A. | |
| Earnings Per Share | N.A. | Current yield | N.A. | |
| Shares Outstanding | N.A. | Dividend Info | ||
| Market Cap | N.A. | |||
|
||||
|
|
